Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
BEOVU (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
BEOVU
Date registered
Evaluation commenced
Decision date
Approval time
196 (255 working days)
Active ingredients
brolucizumab
Registration type
EOI
Indication
BEOVU is indicated for the treatment of:
- Neovascular (wet) age-related macular degeneration (AMD),
- Diabetic macular oedema (DME).